| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Plasmid DNA Manufacturing Market Size Worth $1.51 Billion by 2030: Grand View Research, Inc.
By: PR Newswire Association LLC. - 05 Oct 2022Back to overview list

SAN FRANCISCO, Oct. 5, 2022 /PRNewswire/ -- The global plasmid DNA manufacturing market size is expected to reach USD 1.51 billion by 2030, registering a CAGR of 13.71% over the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, combined with the wide application scope of plasmid DNA in the healthcare industry is expected to drive the industry growth. Plasmid DNA can be used directly for therapeutic applications, such as the production of vaccine antigens or gene therapy. Moreover, it can be utilized for various research purposes, such as gene cloning, gene mapping, etc. The rising number of patients choosing gene therapy is expected to drive industry growth in the coming years.

Grand View Research Logo

Key Industry Insights & Findings from the report:

  • The GMP grade type segment held the largest revenue share in 2021. GMP-grade plasmid DNAs are broadly utilized in pre-clinical trials in gene therapy or vaccination including bio distribution and toxicology studies.
  • The clinical therapeutics segment dominated the global industry in 2021 owing to the increased importance of plasmid DNA for clinical research applications in genetic vaccination.
  • The infectious diseases segment held a significant revenue in 2021. DNA plasmid is effectively utilized in the treatment of several infectious disorders as it delivers a strong immunity via vaccine antigen and prevents pathogen infections.
  • The cell & gene therapy application segment led the industry in 2021 owing to the high demand for gene therapy for the treatment of several inherited diseases and genetic disorders.
  • North America was the dominant regional market in 2021 due to improved healthcare infrastructure, high disposable income, presence of a substantial number of centers and institutes that are engaged in R&D of advanced therapies, and increased adoption of advanced therapies in the region.
  • Asia Pacific is anticipated to register the fastest CAGR during the forecast years on account of the increasing R&D activities in this field and the presence of key players.

Read 150 page full market research report for more Insights, "Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Plasmid DNA Manufacturing Market Growth & Trends

According to, the number of cell & gene therapies across global pipeline programs (Phase I to Phase III trials) increased from 289 in 2018 to 327 in 2022. Furthermore, the U.S. FDA provides constant support for innovations in the advanced therapy arena via several policies concerning product manufacturing. With increased cell and gene therapy products, the industry will see an increased need for manufacturing plasmid DNA on a larger scale. The COVID-19 pandemic is anticipated to positively impact industry growth. For instance, in September 2021, India approved the first COVID-19 DNA vaccine. It is the world's first COVID-19 DNA vaccine manufactured in partnership with DBT-BIRAC as part of Mission COVID Suraksha.

Circular DNA is used in India's ZyCoV-D vaccination to protect against COVID-19 infection. Furthermore, key entities in the global industry are undertaking various strategic initiatives to strengthen their market presence, which is also expected to propel growth. For instance, in June 2022, BioCina announced the expansion of the production of plasmid DNA in a new dedicated GMP suite to its offering of CDMO services. The suite has a single-use fermentation capacity of up to 300 L and appropriately scaled downstream processing machinery.

Plasmid DNA Manufacturing Market Segmentation

Grand View Research has segmented the global plasmid DNA manufacturing market based on grade, development phase, application, disease, and region:

Plasmid DNA Manufacturing Market - Grade Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • R&D Grade
  • GMP Grade

Plasmid DNA Manufacturing Market - Development Phase Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Pre-clinical Therapeutics
  • Clinical Therapeutics
  • Marketed Therapeutics

Plasmid DNA Manufacturing Market - Application Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • DNA Vaccines
  • Cell & Gene Therapy
  • Immunotherapy
  • Others

Plasmid DNA Manufacturing Market - Disease Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Infectious Disease
  • Cancer
  • Genetic Disorder

Plasmid DNA Manufacturing Market - Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

List of Key Players of Plasmid DNA Manufacturing Market

  • Charles River Laboratories
  • VGXI, Inc.
  • Aldevron
  • Kaneka Corp.
  • Nature Technology
  • Cell and Gene Therapy Catapult
  • Eurofins Genomics
  • Lonza
  • Luminous BioSciences, LLC
  • Akron Biotech

Check out more related studies published by Grand View Research:

  • Viral Vectors And Plasmid DNA Manufacturing Market - The global viral vectors and plasmid DNA manufacturing market are expected to reach USD 11.19 billion by 2030, registering a CAGR of 14.71% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growing demand for viral vectors and plasmid DNA for gene therapy has prompted leading market participants to introduce innovative and technologically advanced programs and technologies to increase plasmid DNA production. For instance, In April 2018, GE Healthcare Life Sciences announced the introduction of KUBio BSL 2, a prefabricated, modular bioprocessing facility for the manufacturing of viral vector-based vaccinations, oncolytic virus, and cell and gene therapies.
  • DNA Sequencing Market - The global DNA sequencing market size is expected to reach USD 11.2 billion by 2027, expanding at a CAGR of 11.4%, according to a new report by Grand View Research, Inc. The incorporation of Artificial Intelligence (AI) has increased the utility of genomic data in clinical practices and thus creates a new frontier in the advancement of genomic data analysis. In May 2020, Nvidia Corporation developed new AI tools, genomic sequencing software, and speech recognition technologies to aid the COVID-19 research efforts. Thus, AI accelerates the variant annotation and prioritization in the clinical diagnosis, which drives the market.
  • DNA & Gene Chip Market - The global DNA & gene chip market size is expected to reach USD 10.7 billion by 2025, according to a new report by Grand View Research, Inc., at an 11.4% CAGR during the forecast period. DNA and gene chips have gained much success in providing high throughput capabilities for comprehensive genome studies to enhance disease knowledge and target them. This technology has emerged as a valuable and promising solution across various aspects of disease management. These factors have been driving the market.

Browse through Grand View Research's  Biotechnology Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.


Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519



Grand View Compass | Astra ESG Solutions

Follow Us: LinkedIn | Twitter


Cision View original content:

Copyright 2022 PR Newswire Association LLC. Back to overview list
to the top ↑